Valuing Verastem
Three companies in the IPO
queue have set their price ranges this month, providing valuation benchmarks
for other biotechs looking to go public in 2012. The real question is whether Verastem
Inc. is an outlier or the new norm - the preclinical cancer stem cell
company is seeking a valuation of almost $200 million.